Search Results

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the publication of new preclinical research findings describing the potential utility of the Company’s most advanced cancer immunotherapy platform, selective RORgamma agonists, in adoptive cell therapy applications.

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced that two abstracts highlighting data from ongoing clinical studies of the company’s novel immuno-oncology therapeutic candidate, LYC-55716,

Lycera’s Phase 1b study is expected to enroll a total of approximately 18 patients with metastatic NSCLC.

Lycera Corp. announced presentations of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, to take place during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Lycera has selected multiple tumor types, including non-small-cell lung cancer, squamous cell head and neck cancer, ovarian cancer, urothelial cancer, renal cell cancer, and esophageal / gastric cancer for inclusion in the Phase IIa portion of the ARGON study.

Lycera today announced the initiation of the Phase 2a portion of the company’s Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a first-in-class oral, selective retinoic acid-related orphan receptor-gamma (RORgamma) agonist, designed to reprogram the immune system in patients with advanced, relapsed or refractory solid tumors.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating office

Metters Was Most Recently CEO of Lycera and Previously Led Worldwide Basic Research for Merck